IP Portfolio

USP 6,666,886 Tissue equivalent approach to a   tissue-engineered cardiovascular valve
USP   8,192,348 Engineered blood vessels
USP 10,111,740 Decellularized biologically-engineered tubular grafts
USP 10,105,208 Decellularized biologically-engineered tubular grafts
USP   10,893,928 Decellularized biologically engineered tubular grafts and valves
PCT/US2017/026204 Decellularized biologically engineered tubular grafts and valves
PCT/US2018/026502 Tri-tube heart valve for strong commissures
PCT/US17/64559 Venous valves
PCT/US18/40510 Tissue grafts
US   62/645,698 & 62/652,848 Alternative stent tri-cuspid
US   62/674,487 Sutureless valve
US   62/507,758 Covered stent
US   62/674,494 & 62/674,513 Engineered tissue valves
US   62/684,147 Orthotopic or inverted tricuspid


Vascudyne Image

Vascudyne Receives BioBusiness Award from Regenerative Medicine Minnesota for Treatment of Nerve Injury

VASA Conference Image

Vascudyne Announces Presentation of First Clinical Results of TRUE AVC™ in Hemodialysis Access at the VASA Conference

Vascudyne Lab

Regenerative Medicine Company Vascudyne Relocates to High Capacity GMP Manufacturing Facility

Autm better world project image

Vascudyne’s TRUE Tissue Technology is a Top 3 2022 Better World Project Award Finalist

Regenerative Medicine Vascular Graft for Hemodialysis Access

Regenerative Medicine Company Vascudyne Closes $10 Million Series A Financing

Vascudyne announces successful First Human Use of TRUE™ Vascular Graft for hemodialysis access

Vascudyne’s CSO presents at the Heart Valve Society Meeting on tissue remodeling of engineered valved conduit evaluated at 52 weeks in the growing lamb

Lab-created heart valves can grow with the recipient article published in Science Translational Medicine

Proud Member of:

7 + 8 =

Copyright 2021 | Vascudyne, Inc.